Neuroone Medical Technologies Corporation · NASDAQ:NMTC
Neuroone Medical Technologies — Investor Presentation (December 2025)
19 slides from Neuroone Medical Technologies's investor presentation, Dec 22, 2025
Slide 1: Corporate Presentation December 2025
I̖͔̖͔͋ǻɦۯ ŷ͔ɦͧɦ̅ǻʱ̖̅ TɦɊɦ˾ɂɦ͔ۯԽԻԽՁ Ĭ ƍT žנۯĬĤƛI ɕϒǻ̅Ɋʱ̅ʒۯĬɦΑ͔̖ͧɊʱɦ̅Ɋɦ
Slide 2: Forward-looking statements
Խ Ĭ ƍT žנۯĬĤƛI ƛʞʱͧ ۯ ͔͋ɦͧɦ̅ǻʱ̖̅ ۯ Ɋ̖̅ǻʱ̅ͧ ۯ ʇ̖͔ϖǻ͔ɕ ֱ ˠ̖̖˗ʱ̅ʒ ۯ ͧǻɦ˾ɦ̅ͧ ۯ ϖʱʞʱ̅ ۯ ʞɦ ۯ ˾ɦǻ̅ʱ̅ʒ ۯ ̖ʇ ۯ ƍɦɊʱ̖̅ ۯ ԽՄ ۯ ̖ʇ ۯ ʞɦ ۯ ƍɦɊΑ͔ʱʱɦͧ ۯ Ɋ ۯ ̖ʇ ۯ ԼՆԿԿ כ ۯ ǻͧ ۯ ǻ˾ɦ̅ɕɦɕכ ۯ ǻ̅ɕ ۯ ƍɦɊʱ̖̅ ۯ ԽԼ _ ۯ ̖ʇ ۯ ʞɦ ۯ ƍɦɊΑ͔ʱʱɦͧ ۯ _ϟɊʞǻ̅ʒɦ ۯ Ɋ ۯ ̖ʇ ۯ ԼՆԿՀ כ ۯ ǻͧ ۯ ǻ˾ɦ̅ɕɦɕ ל ۯ _ϟɊɦ͋ ۯ ʇ̖͔ ۯ ͧǻɦ˾
Slide 3: Company overview
Կ Ĭ ƍT žנۯĬĤƛI ‰T ֽ Iˠɦǻ͔ɦɕ Կۯ‰T ۯՁԼԻ֛˗֜ۯɊˠɦǻ͔ɦɕۯ͔̖͋ɕΑɊͧۯʇ̖͔ۯΑͧɦۯʱ̅ۯʞɦۯ ɂ͔ǻʱ̅כۯۯϖʱʞۯʞɦۯ̖̅ˠϤۯ‰T ۯɊˠɦǻ͔ɦɕۯ͔̖͋ɕΑɊۯ ʞǻۯΑͧɦͧۯʞɦۯͧǻ˾ɦۯͧ__ۯɦˠɦɊ͔̖ɕɦۯʇ̖͔ۯɂ̖ʞۯ ɕʱǻʒ̖̅ͧʱɊۯǻ̅ɕۯʞɦ͔ǻ͋ɦΑʱɊۯǻ͋͋ˠʱɊǻʱ̖̅ͧלۯ Լۯ‰T ۯՁԼԻ֛˗֜ۯɊˠɦǻ͔ɦɕۯ͔̖͋ɕΑɊۯʇ̖͔ۯΑͧɦۯʱ̅ۯ ʇǻɊʱǻˠۯ̅ɦ͔ϒɦכۯʞɦۯŁ̅ɦƀ‰؋ۯƛ͔ʱʒɦ˾ʱ̅ǻˠۯĬɦ͔ϒɦۯ ɂˠǻʱ̖̅ۯƍϤͧɦ
Slide 4: Thin film platform and flexibility
Հ Ĭ ƍT žנۯĬĤƛI ƛʞʱ̅ۯ‰ʱˠ˾ۯ֏ۯ‰ˠɦϟʱɂʱˠʱϤ • ¡ʱʒʞˠϤۯʇˠɦϟʱɂˠɦۯɕɦͧʱʒ̅ۯ͔̖͋ϒʱɕɦͧۯ̅ɦϖۯ̖͋ʱ̖̅ͧۯʇ̖͔ۯ ͧΑ͔ʒʱɊǻˠۯ͋ˠǻɊɦ˾ɦ̅ۯǻ̅ɕۯ̖͋ɦ̅ʱǻˠˠϤۯͧ˾ǻˠˠɦ͔ۯ ɂ̖͔ʱ̅ʒ֭ͧʱ̅Ɋʱͧʱ̖̅ͧ • ę̖ϖɦ͔ۯʱ̅ʇˠǻ˾˾ǻʱ̖̅ۯɊ̖˾͋ǻ͔ɦɕۯ̖ۯɂΑˠ˗ʱɦ͔ۯ ɦˠɦɊ͔̖ɕɦͧ Լ • _̅ǻɂˠɦͧۯ͋ǻʱ͔ʱ̅ʒۯ̖ʇۯɕʱǻʒ̖̅ͧʱɊۯǻ̅ɕۯʞɦ͔ǻ͋ɦΑʱɊۯ ͔̖͋ɊɦɕΑ͔ɦͧۯΑͧʱ̅ʒۯʞɦۯͧǻ˾ɦۯ ͧ__ ۯ • ‰ʱ͔ͧۯՁԼ
Slide 5: Scientific advisory board and company background
Ձ Ĭ ƍT žנۯĬĤƛI • ĤǻϤ̖ۯ Iˠʱ̅ʱɊۯ ɂɦʒǻ̅ۯɦͧʱ̅ʒۯɦɊʞ̖̅ˠ̖ʒϤۯ ʱ̅ ۯ ͔͋ɦ ֱ Ɋˠʱ̅ʱɊǻˠۯ ˾̖ɕɦˠͧۯǻ̅ɕۯ Ɋˠʱ̅ʱɊǻˠۯ ͔ɦͧɦǻ͔Ɋʞۯ ʱ̅ ۯ ԽԻԼՁ • ĤǻϤ̖ۯ Iˠʱ̅ʱɊۯ ˠɦǻɕʱ̅ʒۯ ̅ɦΑ͔̖ˠ̖ʒʱͧכۯ T͔לۯ Nj̖͔͔ɦˠˠכۯ Ɋʞǻʱ͔ͧۯ ʞɦۯ ĬɦΑ͔̖Ł̅ɦ ۯ ƍɊʱɦ̅ʱʇʱɊۯ ɕϒʱ̖͔ͧϤۯ A̖ǻ͔ɕ • ‰ʱ͔ͧۯɊ̖˾˾ɦ͔Ɋʱǻˠۯ ʞΑ˾ǻ̅ۯΑͧɦۯ̖ʇۯ_ϒ̖ ؋ ۯ I̖͔ʱɊǻˠۯ _ˠɦɊ͔̖ɕɦͧۯ ͋ɦ͔ʇ̖͔˾ɦɕۯǻ
Slide 6: Expanded partnership with Zimmer Biomet
Ճ Ĭ ƍT žנۯĬĤƛI _ϟ͋ǻ̅ɕɦɕۯ͋ǻ͔̅ɦ͔ͧʞʱ͋ۯ̖ۯʱ̅ɊˠΑɕɦۯɕʱ͔ͧʱɂΑʱ̖̅ۯۯ͔ʱʒʞͧۯʇ̖͔ۯ ĬɦΑ͔̖Ł̅ɦͧ ۯ Ł̅ɦƀ‰؋ۯ ɂˠǻʱ̖̅ۯƍϤͧɦ˾ۯʱ̅ۯʞɦۯɂ͔ǻʱ̅ • ԛԿۯ˾ʱˠˠʱ̖̅ۯˠʱɊɦ̅ͧʱ̅ʒۯʇɦɦۯ • Tʱ͔ͧʱɂΑʱ̖̅ۯ͔ʱʒʞͧۯʱ̅ۯƨƍۯǻ̅ɕۯͧɦˠɦɊۯŁƨƍۯɊ̖Α͔̅ʱɦͧ • _ϟ͋ɦɊɦɕۯ̖ۯɂ̖̖ͧۯĬɦΑ͔̖Ł̅ɦۯ͔ɦϒɦ̅Αɦۯʒ͔̖ϖʞۯǻ̅ɕۯ͔̖͋ʇʱǻɂʱˠʱϤ • ǰʱ˾˾ɦ͔ۯʱͧۯǻۯϖ̖͔ˠɕϖʱɕɦۯˠɦǻɕɦ͔ۯʱ̅ۯ
Slide 7: Brain ablation market
Մ Ĭ ƍT žנۯĬĤƛI A͔ǻʱ̅ۯ ɂˠǻʱ̖̅ ŷǻ͔˗ʱ̖̅ͧ̅ͧ _͋ʱˠɦ͋ͧϤۯ֤Tʱǻʒ̖̅ͧʱɊۯŁ̅ˠϤ֜ ƍ͋ʱ̅ǻˠۯI̖͔ɕۯƍʱ˾Αˠǻʱ̖̅ۯ ֤AǻɊ˗ۯŷǻʱ̅֜ ԛԼԻԻĤ ԛՁԻԻĤ ԛԼA ԛԿA ԛԼԻԻĤ ԛՁA ԛԼԻA ԛԼA T͔ΑʒۯTɦˠʱϒɦ͔Ϥ ԛԻ ԛԼԻA ɊΑǻˠۯĤǻ͔˗ɦ ŷ̖ɦ̅ʱǻˠۯĤǻ͔˗ɦۯƍʱϼɦ ԼלۯI̖˾͋ǻ̅Ϥۯɕǻǻۯ̖̅ۯʇʱˠɦۯ ŁΑ͔ۯɦˠɦɊ͔̖ɕɦۯ͋ˠǻʇ̖͔˾ۯǻɕɕ͔ɦͧͧɦͧۯ˾Αˠʱ ֱ ɂʱˠˠʱ̖̅ۯԛۯ ǻ̅ɕۯʒ͔̖ϖʱ̅ʒۯ˾ǻ͔
Slide 8: Technology Platform
Յ Ĭ ƍT žנۯĬĤƛI ƛɦɊʞ̖̅ˠ̖ʒϤۯŷˠǻʇ̖͔˾
Slide 9: Application status and use case
Ն Ĭ ƍT žנۯĬĤƛI ͋͋ˠʱɊǻʱ̖̅ ƍǻΑͧ ƨͧɦۯIǻͧɦ ŷ͔̖ɕΑɊ Tʱǻʒ̖̅ͧʱɊ IΑ͔͔ɦ̅ˠϤۯ˾ǻ͔˗ɦɦɕۯɂϤۯۯ ǰʱ˾˾ɦ͔ۯAʱ̖˾ɦ ƀɦɊ̖͔ɕʱ̅ʒۯɂ͔ǻʱ̅ۯǻɊʱϒʱϤۯ ŷˠǻɊɦɕۯ̖̅ۯͧΑ͔ʇǻɊɦۯ̖ʇۯɂ͔ǻʱ̅ۯ _ϒ̖؋ۯI̖͔ʱɊǻˠۯ_ˠɦɊ͔̖ɕɦͧ Tʱǻʒ̖̅ͧʱɊ IΑ͔͔ɦ̅ˠϤۯ˾ǻ͔˗ɦɦɕۯɂϤۯۯ ǰʱ˾˾ɦ͔ۯAʱ̖˾ɦ ƀɦɊ̖͔ɕʱ̅ʒۯɂ͔ǻʱ̅ۯǻɊʱϒʱϤۯ ŷˠǻɊɦɕۯTɦɦ͋ɦ͔ۯÅ̖̅ۯʞɦۯA͔ǻʱ̅ۯ _ϒ̖؋ۯͧ__ۯ_ˠɦɊ͔̖
Slide 10: Summary of product features
ԼԻ Ĭ ƍT žנۯĬĤƛI ƍΑ˾˾ǻ͔Ϥ • Å̅Ɋ͔ɦǻͧɦɕۯͧʱʒ̅ǻˠۯɊˠǻ͔ʱϤۯ͔֭ɦɕΑɊɦɕۯ̖̅ʱͧɦۯɕɦͧʱʒ̅ Լ • I̖͔ʱɊǻˠۯɕɦϒʱɊɦۯʞʱ̅̅ɦ͔ۯ֏ۯˠʱʒʞɦ͔ۯʞǻ̅ۯɊ̖˾͋ɦʱʱϒɦۯɕɦϒʱɊɦͧ • ͧ__ۯ ֽ ۯ Aɦɦ͔ۯǻɊʱˠɦۯʇɦɦɕɂǻɊ˗ۯɕΑ͔ʱ̅ʒۯɂ͔ǻʱ̅ۯʱͧͧΑɦۯʱ̅ͧɦ͔ʱ̖̅ • A̖ʞۯ͔̖͋ɕΑɊۯˠʱ̅ɦͧۯǻ͔ɦۯɕʱ͔ͧʱɂΑɦɕۯɂϤۯǰʱ˾˾ɦ͔ۯAʱ̖˾ɦ ͋͋ˠʱɊǻʱ̖̅ͧ • _͋ʱˠɦ͋ͧϤۯͧΑ͔ʒɦ͔Ϥۯʇ̖͔ۯɂ͔ǻʱ̅ۯ˾ǻ͋
Slide 11: 510(k) clearance summary
ԼԼ Ĭ ƍT žנۯĬĤƛI ‰T ۯՁԼԻ֛˗֜ۯIˠɦǻ͔ǻ̅Ɋɦ ƍΑ˾˾ǻ͔Ϥ • Ł̅ɦۯ ͔̖͋ɊɦɕΑ͔ɦۯ ʇ̖͔ۯɕʱǻʒ̖̅ͧʱɊۯǻ̅ɕۯʞɦ͔ǻ͋ɦΑʱɊۯɦϟ͋ɦɊɦɕۯ̖ۯۯͧǻϒɦۯ ʱ˾ɦכۯ˾̖̅ɦϤۯǻ̅ɕۯ̖ۯ ʱ˾͔̖͋ϒɦۯ ͋ǻʱɦ̅ ۯ ̖ΑɊ̖˾ɦͧۯ • ƛɦ˾͋ɦ͔ǻΑ͔ɦ ֱ ʒΑʱɕɦɕۯǻɂˠǻʱ̖̅ۯ͔̖͋ϒʱɕɦͧۯǻɕɕʱʱ̖̅ǻˠۯͧǻʇɦϤۯ˾ɦǻͧΑ͔ɦ • Tɦͧʱʒ̅ɦɕۯ̖ۯ͔ɦɕΑɊɦۯ̅Α˾ɂɦ͔ۯ̖ʇۯ͔̖͋ɊɦɕΑ͔ɦͧۯǻ̅ɕۯʞ̖ͧ͋ʱǻˠʱϼǻʱ̖̅ͧ • ƨͧɦͧۯϖ
Slide 12: Capital equipment single use
ԼԽ Ĭ ƍT žנۯĬĤƛI ‰T ۯՁԼԻ֛˗֜ۯIˠɦǻ͔ǻ̅Ɋɦ Iǻ͋ʱǻˠۯ_͑Αʱ͋˾ɦ̅ ƍʱ̅ʒˠɦۯƨͧɦן ƀ‰ۯ ɊɊɦ̖͔ͧͧʱɦͧ ƍʱ̅ʒˠɦۯƨͧɦן ƛĬƀ‰ۯŷ͔̖ɂɦۯ ֏ۯIǻ̅̅Αˠǻ ƨͧɦןۯTʱǻʒ̖̅ͧʱɊ֭ƛʞɦ͔ǻ͋ɦΑʱɊ ƀɦɊɦʱϒɦɕۯՁԼԻ֛˗֜ۯɊˠɦǻ͔ǻ̅Ɋɦۯʇ͔̖˾ۯ‰T ۯʱ̅ۯ ΑʒΑͧۯԽԻԽՁכ Å̅ʱʱǻˠۯɊǻͧɦͧۯͧΑɊɊɦͧͧʇΑˠˠϤۯɊ̖˾͋ˠɦɦɕۯǻۯƨ̅ʱϒɦ͔ͧʱϤۯ¡̖ͧ͋ʱǻˠͧۯʱ̅ۯ Iˠɦϒɦˠǻ̅ɕۯ Ł̅ɦƀ‰ ؋ ۯ ƛ͔ʱʒɦ˾ʱ̅ǻˠۯĬɦ͔ϒɦۯ ɂ
Slide 13: Cylindrical electrodes and solutions
ԼԿ Ĭ ƍT žנۯĬĤƛI ƍΑ˾˾ǻ͔Ϥ • ŷɦ͔ɊΑǻ̅ɦ̖ΑͧˠϤۯ͋ˠǻɊɦɕۯ͋ǻɕɕˠɦۯɦˠɦɊ͔̖ɕɦͧۯʇ̖͔ۯͧ͋ʱ̅ǻˠۯɊ̖͔ɕۯͧʱ˾Αˠǻʱ̖̅ۯ • ɂˠɦۯ̖ۯͧʱ˾Αˠǻɦۯɂ͔̖ǻɕˠϤۯǻ̅ɕۯ͔͋ɦɊʱͧɦˠϤۯǻ͔ʒɦۯʱͧͧΑɦ • ƍΑɊɊɦͧͧʇΑˠˠϤۯɊ̖˾͋ˠɦɦɕۯʱ̅ʱʱǻˠۯɦͧʱ̅ʒۯʇ̖͔ۯɕΑ͔ǻɂʱˠʱϤۯǻ̅ɕۯͧʱ˾Αˠǻʱ̖̅ۯʇ̖͔ۯՁ ֽ Ϥɦǻ͔ۯΑͧɦۯʇ̖͔ۯ͔ɦɊ̖͔ɕʱ̅ʒۯǻ̅ɕۯͧʱ˾Αˠǻʱ̖̅ • ɕϒʱ̖͔ͧϤۯA̖ǻ͔ɕۯ̖ʇۯˠɦǻɕʱ̅ʒۯǻ̅ɦͧ
Slide 14: Drug delivery platform
ԼՀ Ĭ ƍT žנۯĬĤƛI Tɦͧʱʒ̅ɦɕۯ̖ۯˠɦϒɦ͔ǻʒɦۯ̖Α͔ۯ ͧ__ ۯ ͋ˠǻʇ̖͔˾ۯɦ̅ǻɂˠʱ̅ʒۯɕ͔Αʒۯɕɦˠʱϒɦ͔Ϥۯװۯɂ͔ǻʱ̅ۯǻɊʱϒʱϤۯ͔ɦɊ̖͔ɕʱ̅ʒ ŷ͔ɦ ֱ T͔Αʒۯ Tɦˠʱϒɦ͔Ϥ ƀɦɊ̖͔ɕۯA͔ǻʱ̅ۯۯۯۯۯۯۯۯۯۯ ɊʱϒʱϤۯϖʱʞۯ ͧ__ ۯ _ˠɦɊ͔̖ɕɦ֛ͧ֜ T͔ΑʒۯTɦˠʱϒɦ͔Ϥ LjʱǻۯIǻ̅̅Αˠǻۯ Å̅ͧɦ͔ɦɕۯƛʞ͔̖Αʒʞۯ ͧ__ ۯ _ˠɦɊ͔̖ɕɦ֛ͧ֜ ŷ̖ͧ ֱ T͔ΑʒۯTɦˠʱϒɦ͔Ϥ ƀɦɊ̖͔ɕۯA͔ǻʱ̅ۯۯۯۯۯۯۯۯۯۯۯۯۯۯۯۯ
Slide 15: Scientific advisory board and management
ԼՁ Ĭ ƍT žנۯĬĤƛI ƍɊʱɦ̅ʱʇʱɊۯ ɕϒʱ̖͔ͧϤۯA̖ǻ͔ɕ Ĥǻ̅ǻʒɦ˾ɦ̅ۯƛɦǻ˾ Ĥǻ͔˗ۯIʞ͔ʱͧʱǻ̖̅ͧ̅ ƍɦϒɦۯĤɦ͔ɦ̅ͧ ƀ̖̅ۯĤɊIˠΑ͔ʒ Tǻϒɦۯƀ̖ͧǻ I̖ ֱ ‰̖Α̅ɕɦ͔כۯAΑͧʱ̅ɦͧͧۯTɦϒɦˠ̖͋˾ɦ̅ۯ Tʱ͔ɦɊ̖͔כۯĤɦɕʱɊǻˠۯƍǻˠɦͧۯęʱǻʱ̖ͧ̅ IʞʱɦʇۯƛɦɊʞ̖̅ˠ̖ʒϤۯŁʇʇʱɊɦ͔ Iʞʱɦʇۯ‰ʱ̅ǻ̅ɊʱǻˠۯŁʇʇʱɊɦ͔ ŷ͔ɦͧʱɕɦ̅ۯ֏ۯIʞʱɦʇۯ _ϟɦɊΑʱϒɦۯŁʇʇʱɊɦ͔ Iʞ͔ʱͧۯLj̖ˠ˗ɦ͔ _ϒǻ̅ۯ̖Αˠɦ Iǻ˾ʱˠ̖ۯTʱ
Slide 16: Financial highlights
ԼՃ Ĭ ƍT žנۯĬĤƛI • Tɦɂۯʇ͔ɦɦۯɂǻˠǻ̅Ɋɦۯͧʞɦɦ • TɦɊ͔ɦǻͧʱ̅ʒۯɂΑ͔̅ۯ͔ǻɦۯʱ̅ۯ‰ǘԽԻԽՁ • ‰ǘԽԻԽՁۯ‰ʱ̅ǻ̅Ɋʱǻˠͧן o žՀۯԽԻԽՁۯ͔̖͋ɕΑɊۯ͔ɦϒɦ̅Αɦۯ̖ʇۯԛԽלՄĤ ֤ՆԻՄێۯʱ̅Ɋ͔ɦǻͧɦۯϒͧלۯžՀۯԽԻԽՀ֥ o ‰ǘۯԽԻԽՁۯ͔̖͋ɕΑɊۯ͔ɦϒɦ̅Αɦۯ̖ʇۯԛՆלԼĤۯ ֤ԼՃԿێۯʱ̅Ɋ͔ɦǻͧɦۯϒͧלۯ‰ǘԽԻԽՀ֥ o ‰ǘԽԻԽՁۯ͔̖͋ɕΑɊۯʒ͔̖ͧͧۯ˾ǻ͔ʒʱ̅ۯ̖ʇۯՁՃלՁێ • Ĭɦϖۯ̖͋ɦ̅ʱǻˠۯ͋ǻ͔̅ɦ͔ͧʞʱ͋ͧۯʇ̖ɊΑͧɦɕۯ̖̅
Slide 17: Upcoming catalysts
ԼՄ Ĭ ƍT žנۯĬĤƛI • ǰʱ˾˾ɦ͔ Aʱ̖˾ɦۯ Ł̅ɦƀ‰ ؋ۯ ɂˠǻʱ̖̅ۯƍϤͧɦ˾ۯʇΑˠˠۯˠǻΑ̅Ɋʞ • Ł̅ɦƀ‰ ؋ۯƛ͔ʱʒɦ˾ʱ̅ǻˠۯĬɦ͔ϒɦۯ ɂˠǻʱ̖̅ۯƍϤͧɦ˾ۯ‰T ۯɊˠɦǻ͔ǻ̅Ɋɦۯʱ̅ۯ ΑʒΑͧۯԽԻԽՁ o ŷ˷͙ɇ˦͙ʒǻˁې̵ɇγɇ˦Ͳɇېʒ˦ېȫǻˁɇ˦ȶǻ̵ېԞԜԞԤېɨ˷̵ېɨǻȫʒǻˁې̬ǻʒ˦ېǻȣˁǻ͙ʒ˷˦ې͈υ͈͙ɇ˟ • _ˠɦɊ͔̖ɕɦۯ͔ɦϒɦ̅Αɦۯʒ͔̖ϖʞۯʱ̅ۯ‰ǘԽԻԽՃ • ŷ̖ɦ̅ʱǻˠۯ̖̅̅ ֱ ɕʱˠΑʱϒɦۯˠʱɊɦ̅ͧʱ̅ʒۯǻʒ͔ɦɦ˾ɦ̅ۯʇ̖͔ۯ͔
Slide 18: Platform technology summary
ԼՅ Ĭ ƍT žנۯĬĤƛI ŁΑ͔ۯ͋ˠǻʇ̖͔˾ۯɦɊʞ̖̅ˠ̖ʒϤۯ̖ʇۯʞʱ̅ۯʇʱˠ˾ۯɦˠɦɊ͔̖ɕɦۯ͔̖͋ɕΑɊͧۯʱ˾͔̖͋ϒɦۯ̖ΑɊ̖˾ɦͧۯʇ̖͔ۯ͋ǻʱɦ̅ͧۯͧΑʇʇɦ͔ʱ̅ʒۯʇ͔̖˾ۯۯ ̅ɦΑ͔̖ˠ̖ʒʱɊǻˠۯɕʱ̖͔ͧɕɦ͔ͧ ƛʞɦۯ̖̅ˠϤۯɊ̖˾͋ǻ̅Ϥۯϖʱʞۯǻۯͧʱ̅ʒˠɦۯɕɦϒʱɊɦۯʞǻۯɊǻ̅ۯ͋ɦ͔ʇ̖͔˾ۯ˾Αˠʱ͋ˠɦۯɕʱǻʒ̖̅ͧʱɊۯ֏ۯʞɦ͔ǻ͋ɦΑʱɊۯʇΑ̅Ɋʱ̖̅ͧۯͧΑɊʞۯǻͧۯ ͔ɦɊ̖͔ɕʱ̅ʒכۯǻɂˠǻʱ̖̅ۯǻ̅ɕۯͧʱ˾Αˠǻʱ̖̅ۯΑͧʱ̅ʒۯʞɦۯͧǻ˾ɦ
Slide 19: Thank you
ƛʞǻ̅˗ۯϤ̖Α Iʞ͔ʱͧۯƛϤ̖ͧ̅ۯ _ϟɦɊΑʱϒɦۯLjʱɊɦۯŷ͔ɦͧʱɕɦ̅ ĤǰۯĬ̖͔ʞۯ ˾ɦ͔ʱɊǻ Tʱ͔ɦɊןۯՆՀՆ ֽ ՀՆԼ ֽ ՅԽԿՁ ĬĤƛI֣˾ϼʒ͔̖Α͋לΑͧ Ĭ ƍT žנۯĬĤƛI ɕϒǻ̅Ɋʱ̅ʒۯĬɦΑ͔̖ͧɊʱɦ̅Ɋɦ
NeuroOne Medical Technologies — Investor Presentation (December 2025) on 6ix